Serum copper in ovarian carcinoma

Allan J. Jacobs, Gara M. Sommers, Janice H. Axelrod, Andrew E. Galakatos, Ming‐Shian ‐S Kao, H. Marvin Camel

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

The serum copper and CA 125 levels of 31 patients with epithelial ovarian carcinoma were determined. Serum copper was elevated in seven patients and CA 125 was elevated in 22 patients. A rise in serum CA 125 always was associated with disease progression. In comparison, serum copper fluctuation did not correlate with the natural history of the malignancy. We concluded that serum copper determination has no use in epithelial ovarian carcinoma management.

Original languageEnglish
Pages (from-to)1015-1017
Number of pages3
JournalCancer
Volume61
Issue number5
DOIs
StatePublished - Mar 1 1988

Fingerprint Dive into the research topics of 'Serum copper in ovarian carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Jacobs, A. J., Sommers, G. M., Axelrod, J. H., Galakatos, A. E., Kao, MS. S., & Camel, H. M. (1988). Serum copper in ovarian carcinoma. Cancer, 61(5), 1015-1017. https://doi.org/10.1002/1097-0142(19880301)61:5<1015::AID-CNCR2820610526>3.0.CO;2-T